Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target boosted by Roth Capital from $170.00 to $210.00 in a research note published on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently weighed in on MDGL. Evercore ISI restated an outperform rating and set a $175.00 price objective (up from $140.00) on shares of Madrigal Pharmaceuticals in a research report on Thursday, February 8th. HC Wainwright assumed coverage on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 29th. They set a buy rating and a $54.00 price objective for the company. Zacks Investment Research cut shares of Madrigal Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, January 9th. JMP Securities upped their price objective on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an outperform rating in a research report on Friday, October 13th. Finally, BidaskClub upgraded shares of Madrigal Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Saturday, January 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $154.20.
Madrigal Pharmaceuticals (NASDAQ MDGL) opened at $135.93 on Friday. The firm has a market cap of $1,900.00, a price-to-earnings ratio of -55.26 and a beta of 1.19. Madrigal Pharmaceuticals has a 12-month low of $13.09 and a 12-month high of $154.75.
COPYRIGHT VIOLATION NOTICE: “Madrigal Pharmaceuticals (MDGL) PT Raised to $210.00 at Roth Capital” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/02/13/madrigal-pharmaceuticals-mdgl-pt-raised-to-210-00-at-roth-capital.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.